Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $350.0 million.

  • IDEAYA Biosciences' Long-Term Investments rose 2492.86% to $350.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.0 million, marking a year-over-year increase of 2492.86%. This contributed to the annual value of $405.8 million for FY2024, which is 27754.62% up from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Long-Term Investments is $350.0 million, which was up 2492.86% from $322.1 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Long-Term Investments peaked at $405.8 million during Q4 2024, and registered a low of $7.7 million during Q3 2022.
  • In the last 5 years, IDEAYA Biosciences' Long-Term Investments had a median value of $107.5 million in 2023 and averaged $149.6 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Long-Term Investments soared by 237598.71% in 2021 and then tumbled by 9365.52% in 2022.
  • IDEAYA Biosciences' Long-Term Investments (Quarter) stood at $121.3 million in 2021, then plummeted by 93.14% to $8.3 million in 2022, then skyrocketed by 1192.44% to $107.5 million in 2023, then surged by 277.55% to $405.8 million in 2024, then dropped by 13.77% to $350.0 million in 2025.
  • Its last three reported values are $350.0 million in Q3 2025, $322.1 million for Q2 2025, and $358.7 million during Q1 2025.